drugset / Trial / NCT06179160
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Non-randomizedSequentialOpen-labelTreatment
Summary
This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.
Timeline
- Start
- 2024-01-04
- Primary completion
- 2027-01-01
- Completion
- 2027-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INCB161734 | Unknown | — | — |
| Background | Cetuximab | Monoclonal antibody | — | — |
| Background | FOLFIRI | Other / unclassified | — | — |
| Background | FOLFOX | Unknown | — | — |
| Background | GEMNabP | Unknown | — | — |
| Background | INCA33890 | Unknown | — | — |
| Background | Retifanlimab | Monoclonal antibody | — | — |
| Background | mFOLFIRINOX | Unknown | — | — |